Amarin Corp Plc (AMRN)

[marzan]

Rick, Buying Hikma would never “undo” generic entry or restore exclusivity for Amarin, and no serious acquirer thinks that way. The real implication of Hikma being in play is that generic litigation risk is rising, making settlement or licensing far more rational than endless court battles—especially if a deep-pocketed strategic like Novartis is involved. That dynamic doesn’t require overkill M&A to work; it simply compresses uncertainty, which is exactly what Amarin’s valuation has been missing.

Hikma is unattractive to most big pharma because of its litigation-heavy generics exposure, which limits the buyer universe. Novartis would be a rare exception only because it is already strategically aligned around cardiovascular medicine and is rumored to be interested in Amarin, making it uniquely positioned to resolve—not inherit—conflict through settlement, licensing, or restructuring. In that sense, Hikma’s legal baggage doesn’t compete with the Amarin thesis; it reinforces why Amarin is the cleaner, more valuable asset and why Novartis is the logical endgame player.